NOVEL DELIVERY SYSTEM FOR TOPICAL ANESTHESIA

Information

  • Research Project
  • 6210189
  • ApplicationId
    6210189
  • Core Project Number
    R43GM062051
  • Full Project Number
    1R43GM062051-01
  • Serial Number
    62051
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2000 - 24 years ago
  • Project End Date
    8/31/2002 - 22 years ago
  • Program Officer Name
    FU, YALI
  • Budget Start Date
    9/1/2000 - 24 years ago
  • Budget End Date
    8/31/2002 - 22 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/21/2000 - 24 years ago

NOVEL DELIVERY SYSTEM FOR TOPICAL ANESTHESIA

The use of topically applied anesthetics presents numerous advantages over local injection such as eliminating the patient's pain and fear associated with needle injection, avoiding the risk of introducing infection, reducing the occupational risk of unintentional needle sticks, and limiting first-pass metabolism. To date, the most widely used method of topical anesthesia is EMLA (eutectic mixture of local anesthetics) cream. However, the use of EMLA requires application under a burdensome occlusive dressing and extended periods of contact before becoming effective. The goal of this study is to adapt and optimize a unique, patented skin coating drug delivery system to establish effective delivery of local anesthetics via topical administration. In order to demonstrate the feasibility of this approach, the Specific Aims are to optimize the coating to deliver topical anesthetics, to determine the in vitro percutaneous absorption of local anesthetics released from coatings, to demonstrate the safety of coatings in an animal model, and to evaluate the coatings for efficacy in a pilot human clinical trial. PROPOSED COMMERCIAL APPLICATIONS: The number of procedures requiring local anesthesia and the extent to which local anesthetics are being used is steadily increasing. Significant commercial potential exists for a topical anesthetic drug delivery vehicle that would combine cost effective treatment with improved convenience characteristics.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    107000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:107000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOMEDICAL DEVELOPMENT CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN ANTONIO
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    782163610
  • Organization District
    UNITED STATES